PAM Therapy
Alzheimer's Disease
Pre-clinicalActive
Key Facts
About PAM Theragnostics
PAM Theragnostics is a preclinical-stage biotech company pioneering a vascular-centric approach to Alzheimer's disease (AD). The company's strategy focuses on the enzyme Peptidylglycine Alpha-Amidating Monooxygenase (PAM) as both a diagnostic biomarker and a therapeutic agent to strengthen the blood-brain barrier and slow disease progression. Founded by serial entrepreneur Dr. Andreas Bergmann, the company is funded by regional German/EU grants and is preparing for GMP production, with a First-In-Human trial targeted for 2027. Its unique angle involves learning from healthy centenarians to develop a preventive therapy.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |